In this Issue
Considerations on tomorrow's effectiveness benchmarks.
CHIEF MEDICAL EDITORS’ PAGE
By John R. Laird, MD; and Fabrizio Fanelli, MD
A discussion on the challenges of applying current trial data and improvements that could guide evidence-based decision making.
By Mehdi H. Shishehbor, DO, MPH, PhD
Experts discuss key questions to answer, potential trial designs, and the likelihood that the trials will be undertaken.
With Peter A. Schneider, MD; Thomas Zeller, MD; Osamu Iida, MD; Marianne Brodmann, MD; Krishna Rocha-Singh, MD; and Christopher Metzger, MD
Understanding the cost-effectiveness of new devices and treatment strategies.
By Adam C. Salisbury, MD, MSc; and David J. Cohen, MD, MSc
Considerations unique to a single-payor system.
By Konstantinos Katsanos, MSc, MD, PhD, EBIR
Experts discuss the current era of drug-eluting technologies and what might come next.
With Koen Deloose, MD; Craig Walker, MD; and Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Dr. Juan F. Granada discusses the current climate of preclinical research, lessons learned in evaluating drug-eluting technologies, common misconceptions, and what the future holds.
With Juan F. Granada, MD, FACC
A look at the future of lower extremity imaging over the next 5 years.
By Constantino S. Peña, MD
MEDICAL AFFAIRS CORNERSponsored by Medtronic
By Peter A. Schneider, MD
FEATURED STUDYSponsored by Cardiovascular Systems, Inc.
Discussion and roundtable interview of the LIBERTY 360° study of 1,204 Rutherford class 2 to 6 patients, including 100 Rutherford class 6 patients.
By George L. Adams, MD, MHS; Gary M. Ansel, MD; William A. Gray, MD; and J.A. Mustapha, MD
Prof. Lönn shares his advice on critical aspects of TEVAR procedures, as well as the use of robotics and simulation training in endovascular therapies.